Table 2.
Baseline and change from baseline to week 26 in IWQOL-Lite, PGWB, DTSQ-s, and EQ-5D among subjects with type 2 diabetes participating in a randomized, multicenter, double-dummy study of treatment with exenatide QW, sitagliptin, or pioglitazone (intent-to-treat population)
| Exenatide QW |
Sitagliptin |
Pioglitazone |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n† | Baseline | Change‡ | 95% CI | n† | Baseline | Change‡ | 95% CI | n† | Baseline | Change‡ | 95% CI | |
| IWQOL-Lite | ||||||||||||
| Total score | 132 | 80.67 | 5.15* (1.04) | 3.11–7.19 | 139 | 80.74 | 4.56* (1.02) | 2.56–6.57 | 130 | 79.32 | 1.20§ (1.06) | −0.87–3.28 |
| Physical function | 133 | 73.37 | 6.78* (1.35) | 4.11–9.44 | 141 | 73.75 | 5.81* (1.33) | 3.20–8.42 | 131 | 73.00 | 2.00§ (1.38) | −0.71–4.71 |
| Self-esteem | 133 | 77.81 | 5.88* (1.39) | 3.16–8.61 | 141 | 79.12 | 5.79* (1.36) | 3.11–8.47 | 131 | 76.71 | 3.11 (1.41) | 0.34–5.89 |
| Sexual life | 129 | 83.83 | 5.80* (1.61) | 2.64–8.95 | 132 | 82.38 | 5.02* (1.61) | 1.85–8.18 | 127 | 81.59 | 2.41 (1.63) | −0.79–5.60 |
| Public distress | 132 | 91.03 | 3.86* (1.17) | 1.56–6.15 | 140 | 90.23 | 2.40* (1.14) | 0.16–4.64 | 130 | 88.53 | −0.63§ (1.18) | −2.96–1.70 |
| Work | 131 | 89.74 | 2.79* (1.28) | 0.28–5.30 | 139 | 88.95 | 3.02* (1.25) | 0.57–5.47 | 128 | 87.58 | −1.28§ (1.29) | −3.82–1.26 |
| EQ-5D | ||||||||||||
| Index score | 129 | 0.77 | 0.04* (0.02) | 0.01–0.08 | 139 | 0.78 | 0.05* (0.02) | 0.02–0.08 | 130 | 0.82 | 0.02 (0.02) | −0.01–0.06 |
| Visual analog score | 132 | 74.25 | 4.46* (1.34) | 1.82–7.10 | 139 | 73.10 | 6.04* (1.32) | 3.45–8.64 | 130 | 74.85 | 2.54 (1.37) | −0.16–5.24 |
| PGWB | ||||||||||||
| Global score | 132 | 67.54 | 6.82* (1.00) | 4.85–8.79 | 141 | 69.96 | 6.97* (0.98) | 5.04–8.90 | 130 | 71.60 | 4.78* (1.02) | 2.77–6.79 |
| Anxiety | 132 | 66.32 | 8.40* (1.31) | 5.83–10.97 | 141 | 70.35 | 8.20* (1.28) | 5.68–10.71 | 130 | 70.85 | 5.10* (1.33) | 2.48–7.73 |
| Depressed mood | 133 | 80.23 | 3.84* (1.33) | 1.22–6.45 | 141 | 81.98 | 3.80* (1.30) | 1.24–6.37 | 130 | 84.00 | 3.73* (1.36) | 1.06–6.40 |
| Positive well-being | 133 | 61.92 | 4.65* (1.42) | 1.85–7.44 | 141 | 61.84 | 7.86* (1.39) | 5.12–10.60 | 130 | 64.10 | 5.02* (1.45) | 2.17–7.88 |
| Self control | 133 | 75.11 | 5.53* (1.37) | 2.83–8.22 | 141 | 78.71 | 4.30* (1.34) | 1.67–6.94 | 130 | 83.33 | 3.68* (1.40) | 0.93–6.43 |
| General health | 133 | 65.39 | 9.46* (1.40) | 6.72–12.21 | 141 | 67.84 | 6.95* (1.37) | 4.26–9.65 | 130 | 67.56 | 6.37* (1.43) | 3.56–9.17 |
| Vitality | 133 | 61.20 | 7.46* (1.37) | 4.76–10.16 | 141 | 63.51 | 8.98* (1.35) | 6.33–11.63 | 130 | 65.00 | 6.23* (1.41) | 3.46–9.00 |
| DTSQ | ||||||||||||
| Total score | 121 | 27.99 | 3.96* (0.60) | 2.78–5.15 | 127 | 28.13 | 2.35* (0.59) | 1.19–3.51 | 123 | 26.78 | 2.50* (0.61) | 1.31–3.69 |
| Perceived frequency high blood glucose | 121 | 3.84 | −1.63* (0.17) | −1.96 to −1.30 | 127 | 3.94 | −1.30* (0.17) | −1.63 to −0.97 | 123 | 3.56 | −1.28* (0.17) | −1.62 to −0.94 |
| Perceived frequency low blood glucose | 120 | 0.94 | 0.22 (0.15) | −0.07 to 0.51 | 126 | 1.12 | −0.05 (0.15) | −0.33 to 0.24 | 122 | 0.91 | −0.12 (0.15) | −0.42 to 0.17 |
†Number of subjects with a baseline and postrandomization score.
‡Data are least squares mean changes (and SE).
*P ≤ 0.05 (change from baseline within treatment group).
§P ≤ 0.05 (difference compared with exenatide group at week 26).